Transient diabetes mellitus presenting with diabetic ketoacidosis: a case report

Authors

  • Suresh Kumar Panuganti Department of Pediatrics, Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, India
  • Jeevan Reddy Nukala Department of Pediatrics, Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, India
  • Venkateshwar Vempati NICE Hospital for Women, Newborns and Children, Hyderabad, Telangana, India
  • Sujeeth Kumar Modi Department of Pediatrics, Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, India
  • Pooja N. Patel Department of Pediatrics, Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20243100

Keywords:

Neonatal diabetes, Transient, Sulfonylurea, Hyperglycaemia

Abstract

Neonatal diabetes mellitus (NDM) represents a monogenic form of diabetes mellitus, manifesting with hyperglycemia during the neonatal period. It is relatively a rare condition, affecting an estimated incidence of 1 in every 90,000 live births. Depending on the duration of condition, NDM can be categorized as temporary NDM (TNDM) and permanent NDM (PNDM). We present a case of a 43-day-old infant who presented with diabetic ketoacidosis. Upon evaluation, it was observed that the infant had TNDM, specifically caused by a mutation in the KCNJ11 gene. The infant was initially managed with insulin therapy but was later transitioned to oral sulfonylureas (SU). Initial research suggests that administering SU treatment at an early stage, as opposed to insulin, could enhance neurodevelopmental outcomes in patients who respond well to SU.

References

Letourneau LR, Carmody D, Wroblewski K, Denson AM, Sanyoura M, Naylor RN, et al. Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis. Diabetes Care. 2017;40(10):e147-8.

Lemelman MB, Letourneau L, Greeley SAW. Neonatal Diabetes Mellitus: An Update on Diagnosis and Management. Clin Perinatol. 2018;45(1):41-59.

Støy J, Steiner DF, Park SY, Ye H, Philipson LH, Bell GI. Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord. 2010;11(3):205-15.

Rubio-Cabezas O, Ellard S. Diabetes mellitus in neonates and infants: genetic heterogeneity, clinical approach to diagnosis, and therapeutic options. Horm Res Paediatr. 2013;80(3):137-46.

De Franco E, Flanagan SE, Houghton JA, Lango Allen H, Mackay DJ, Temple IK, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet. 2015;386(9997):957-6.

Liu M, Hodish I, Haataja L, Lara-Lemus R, Rajpal G, Wright J, et al. Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth. Trends Endocrinol Metab. 2010;21(11):652-9.

Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S. Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab. 2007;9(2):28-39.

Besser RE, Flanagan SE, Mackay DG, Temple IK, Shepherd MH, Shields BM, et al. Prematurity and Genetic Testing for Neonatal Diabetes. Pediatrics. 2016;138(3):10.

Proks P, De Wet H, Ashcroft FM. Molecular mechanism of sulphonylurea block of K(ATP) channels carrying mutations that impair ATP inhibition and cause neonatal diabetes. Diabetes. 2013;62(11):3909-19.

Shah B, Kataria A, Gopi R, Mally P. Neonatal diabetes mellitus: current perspective. Res Rep Neonatol 2014;4:55-64.

Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia. 2003;46(7):875-91.

Chakera AJ, Flanagan SE, Ellard S, Hattersley AT. Comment on: Khurana. The diagnosis of neonatal diabetes in a mother at 25 years of age. Diabetes Care 2012;35:e59.

Mohamadi A, Clark LM, Lipkin PH, Mahone EM, Wodka EL, Plotnick LP. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM. Pediatr Diabetes. 2010;11(3):203-7.

Pun P, Clark R, Wan KW, Peverini R, Merritt T. Neonatal Diabetes Mellitus: The Impact of Molecular Diagnosis. NeoReviews.2010;11(6):e306-e31.

Ogilvy-Stuart AL, Beardsall K. Management of hyperglycaemia in the preterm infant. Arch Dis Child Fetal Neonatal Ed. 2010;95(2):F126-31.

Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54(9):2503-13.

Grulich-Henn J, Wagner V, Thon A, Schober E, Marg W, Kapellen TM, et al. Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). Diabet Med. 2010;27(6):709-12.

Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT; Neonatal Diabetes International Collaborative Group. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008;31(2):204-9.

Carmody D, Pastore AN, Landmeier KA, Letourneau LR, Martin R, Hwang JL, et al. Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls. Diabet Med. 2016;33(10):1380-6.

Downloads

Published

2024-10-24

Issue

Section

Case Reports